[go: up one dir, main page]

IS6398A - Lyfjablöndur - Google Patents

Lyfjablöndur

Info

Publication number
IS6398A
IS6398A IS6398A IS6398A IS6398A IS 6398 A IS6398 A IS 6398A IS 6398 A IS6398 A IS 6398A IS 6398 A IS6398 A IS 6398A IS 6398 A IS6398 A IS 6398A
Authority
IS
Iceland
Prior art keywords
formulations
Prior art date
Application number
IS6398A
Other languages
English (en)
Other versions
IS2841B (is
Inventor
Dixon John
Humphries Robert
Jarvis Gavin
Kirk Ian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6398A publication Critical patent/IS6398A/is
Publication of IS2841B publication Critical patent/IS2841B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6398A 1999-12-01 2002-05-27 Samstæða hluta og lyfjasamsetningar IS2841B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations
PCT/SE2000/002378 WO2001039781A1 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
IS6398A true IS6398A (is) 2002-05-27
IS2841B IS2841B (is) 2013-08-15

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6398A IS2841B (is) 1999-12-01 2002-05-27 Samstæða hluta og lyfjasamsetningar

Country Status (32)

Country Link
US (2) US20030032618A1 (is)
EP (2) EP1719526A3 (is)
JP (1) JP2003515565A (is)
KR (1) KR100785953B1 (is)
CN (1) CN1402639A (is)
AR (1) AR033658A1 (is)
AT (1) ATE332698T1 (is)
AU (1) AU781691B2 (is)
BR (1) BR0016043A (is)
CA (1) CA2391161C (is)
CO (1) CO5271717A1 (is)
CY (1) CY1105211T1 (is)
CZ (1) CZ300925B6 (is)
DE (1) DE60029340T2 (is)
DK (1) DK1237559T3 (is)
EE (1) EE05127B1 (is)
ES (1) ES2267591T3 (is)
HU (1) HU230890B1 (is)
IL (1) IL149495A0 (is)
IS (1) IS2841B (is)
MX (1) MXPA02004871A (is)
MY (1) MY128896A (is)
NO (1) NO331215B1 (is)
NZ (2) NZ518904A (is)
PT (1) PT1237559E (is)
RU (1) RU2242232C2 (is)
SE (1) SE9904377D0 (is)
SI (1) SI1237559T1 (is)
SK (1) SK288707B6 (is)
TW (1) TWI251491B (is)
WO (1) WO2001039781A1 (is)
ZA (1) ZA200203707B (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
KR100736024B1 (ko) * 2005-09-21 2007-07-06 주식회사종근당 신규한 클로피도그렐 우선성 광학이성체의 이온교환수지착체와 그 제조방법
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
HRP20200445T1 (hr) 2009-11-11 2020-06-12 Chiesi Farmaceutici S.P.A. Metode liječenja ili prevencije tromboze u stentu
BR112013020377B1 (pt) 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
CA2904523C (en) 2013-03-09 2024-01-09 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
KR102768341B1 (ko) 2017-06-23 2025-02-18 키에시 파르마슈티시 엣스. 피. 에이. 체폐동맥 션트 혈전증의 예방 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
DE69204717T2 (de) * 1991-04-06 1996-04-25 Astra Pharmaceuticals Limited, Kings Langley, Herts ATP-Analogen.
ES2108425T3 (es) * 1993-02-10 1997-12-16 Astra Pharma Prod Analogos de atp sustituidos con n-alquilo-2.
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE19515500A1 (de) * 1995-04-27 1996-10-31 Thomae Gmbh Dr K Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TR199800019T1 (xx) * 1995-07-11 1998-05-21 Astra Pharmaceuticals Limited Trombosit topaklanmas�n� �nleyici yeni maddeler.
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
US20060160887A1 (en) * 2003-07-16 2006-07-20 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
DE60029340D1 (de) 2006-08-24
DE60029340T2 (de) 2007-07-19
CZ20021887A3 (cs) 2002-11-13
CN1402639A (zh) 2003-03-12
SK7502002A3 (en) 2003-02-04
IS2841B (is) 2013-08-15
NZ530058A (en) 2005-04-29
HU230890B1 (hu) 2018-12-28
CA2391161A1 (en) 2001-06-07
AR033658A1 (es) 2004-01-07
NO20022606L (no) 2002-07-11
PT1237559E (pt) 2006-10-31
SE9904377D0 (sv) 1999-12-01
US20030032618A1 (en) 2003-02-13
EP1719526A2 (en) 2006-11-08
NO20022606D0 (no) 2002-05-31
KR20020069201A (ko) 2002-08-29
ZA200203707B (en) 2003-10-29
EP1719526A3 (en) 2007-04-25
MY128896A (en) 2007-02-28
EP1237559B1 (en) 2006-07-12
AU1910901A (en) 2001-06-12
NO331215B1 (no) 2011-11-07
ES2267591T3 (es) 2007-03-16
EE05127B1 (et) 2009-02-16
SK288707B6 (sk) 2019-10-02
HK1047893A1 (en) 2003-03-14
RU2002117296A (ru) 2004-01-20
JP2003515565A (ja) 2003-05-07
AU781691B2 (en) 2005-06-09
TWI251491B (en) 2006-03-21
NZ518904A (en) 2004-02-27
CA2391161C (en) 2010-10-05
MXPA02004871A (es) 2002-08-30
KR100785953B1 (ko) 2007-12-14
DK1237559T3 (da) 2006-10-30
PL355841A1 (en) 2004-05-17
EE200200271A (et) 2003-06-16
BR0016043A (pt) 2002-07-23
HUP0203585A3 (en) 2005-01-28
RU2242232C2 (ru) 2004-12-20
EP1237559A1 (en) 2002-09-11
WO2001039781A1 (en) 2001-06-07
SI1237559T1 (sl) 2007-02-28
US20060270607A1 (en) 2006-11-30
HUP0203585A2 (hu) 2003-03-28
CZ300925B6 (cs) 2009-09-09
ATE332698T1 (de) 2006-08-15
IL149495A0 (en) 2004-03-28
CY1105211T1 (el) 2010-03-03
CO5271717A1 (es) 2003-04-30

Similar Documents

Publication Publication Date Title
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240D0 (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
DE60005976D1 (de) Speicherkkarte
DE60035838D1 (de) Computerbusschienenanordnung
DE60039942D1 (de) Selbstbräununsschaum
DE60025647D1 (de) Festkörperbildaufnahemvorrichtung
PT1130966E (pt) Formulacoes antiparasitarias
DK1237878T3 (da) 4-pyrimidinyl-N-acyl-L-phenylanin
DE60001283D1 (de) Celluloseetherfilme
DE60008422D1 (de) Pour-on formulierungen
EE200200150A (et) Preparaat
DE60010483D1 (de) Heizplattenniederschlagsmesseinheit
IS6398A (is) Lyfjablöndur
DE60045545D1 (de) Klebefolie
DE60001894D1 (de) Busschienenverbindungsstruktur
DE60001649D1 (de) Ziprasidonsuspension
DK1204482T3 (da) Hydrocyklon
DE60011195D1 (de) Narkosemittelverdunster
ATE268116T1 (de) Mesotrion-formulierungen
DE60033003D1 (de) Münzrollmaschine
DE60023130D1 (de) Scharnierarmbefestigung